{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:22:09Z","timestamp":1787718129651,"version":"build-2784847793"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ero.2025.11.018","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T20:04:05Z","timestamp":1767384245000},"page":"90-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tocilizumab in German patients with RA: real-world evidence from the noninterventional studies ARATA and ICHIBAN"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2504-3229","authenticated-orcid":false,"given":"Christof","family":"Specker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Strotkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9617","key":"10.1016\/j.ero.2025.11.018_bib0001","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ero.2025.11.018_bib0002","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ero.2025.11.018_bib0003","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ero.2025.11.018_bib0004","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/eci.10.2","article-title":"The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis","volume":"6","author":"Jones","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.ero.2025.11.018_bib0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3899\/jrheum.120447","article-title":"Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results","volume":"40","author":"Fleischmann","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ero.2025.11.018_bib0006","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/acr.22110","article-title":"Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis","volume":"66","author":"Ogata","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ero.2025.11.018_bib0007","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.018_bib0008","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1002\/art.22193","article-title":"Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials","volume":"54","author":"Zink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ero.2025.11.018_bib0009","unstructured":"ARATA study protocol: Paul Ehrlich Institut. ARATA\u2014a prospective, non-interventional study in Germany to evaluate the long-term effectiveness and tolerability of subcutaneously administered RoActemra\u00ae (Tocilizumab; TCZ) in patients with rheumatoid arthritis in daily clinical practice (as recommended in label) [Internet]. [cited 2025 Nov 6]. Available from:https:\/\/www.pei.de\/SharedDocs\/Downloads\/DE\/awb\/nis-0201-0300\/0261-beoplan.pdf?__blob=publicationFile&v=4"},{"key":"10.1016\/j.ero.2025.11.018_bib0010","unstructured":"ARATA CSR: Paul-Ehrlich-Institut. ARATA\u2014Eine prospektive, nichtinterventionelle Beobachtungsstudie in Deutschland zur Evaluierung der Langzeitwirksamkeit und Vertr\u00e4glichkeit von subkutan verabreichtem RoActemra\u00ae (Tocilizumab) bei Patienten mit rheumatoider Arthritis in der t\u00e4glichen Praxis (wie in der Fachinformation empfohlen) [Internet]. [cited 2024 Apr 10]. Available from: https:\/\/www.pei.de\/SharedDocs\/Downloads\/DE\/awb\/nis-0201-0300\/0261-abschlussb.pdf?__blob=publicationFile&v=1"},{"key":"10.1016\/j.ero.2025.11.018_bib0011","unstructured":"ICHIBAN study protocol: Paul Ehrlich Institut. ICHIBAN\u2014a prospective, non-interventional multi-center observational study to evaluate the long-term effectiveness and safety of tocilizumab in patients with active rheumatoid arthritis in daily practice [Internet]. [cited 2025 Nov 6]. Available from:https:\/\/www.pei.de\/SharedDocs\/Downloads\/DE\/awb\/nis-0001-0100\/0074-beoplan.pdf?__blob=publicationFile&v=2"},{"key":"10.1016\/j.ero.2025.11.018_bib0012","unstructured":"ICHIBAN CSR: Paul-Ehrlich-Institut. ICHIBAN\u2014a prospective, non-interventional multi-center observational study to evaluate the long-term effectiveness and safety of tocilizumab in patients with active rheumatoid arthritis in daily practice [Internet]. [cited 2024 Apr 28]. Available from: https:\/\/www.pei.de\/SharedDocs\/Downloads\/DE\/awb\/nis-0001-0100\/0074-abschlussb.pdf?__blob=publicationFile&v=2"},{"key":"10.1016\/j.ero.2025.11.018_bib0013","first-page":"1657","article-title":"The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age","volume":"40","author":"Specker","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ero.2025.11.018_bib0014","unstructured":"Data from the ICHIBAN study on file at sponsor."},{"key":"10.1016\/j.ero.2025.11.018_bib0015","unstructured":"Specker C, Alberding A, Aringer M. Verbesserung des HbA1c bei RA Patienten mit Diabetes unter Tocilizumab [Internet]. Poster 1550 presented at: 46. Kongress der Deutschen Gesellschaft f\u00fcr Rheumatologie (DGRh); 2018 Sep 19 to 22: Mannheim, Germany. [cited 2025 Jan 22]. https:\/\/www.egms.de\/static\/en\/meetings\/dgrh2018\/18dgrh135.shtml"},{"issue":"suppl 10","key":"10.1016\/j.ero.2025.11.018_bib0016","article-title":"Safety and effectiveness of tocilizumab in patients with renal insufficiency in the non-interventional study ICHIBAN [abstract]","volume":"72","author":"Specker","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ero.2025.11.018_bib0017","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1007\/s10067-019-04613-2","article-title":"Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis","volume":"38","author":"JJ","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ero.2025.11.018_bib0018","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.018_bib0019","unstructured":"Data from the ARATA study on file at sponsor."},{"key":"10.1016\/j.ero.2025.11.018_bib0020","article-title":"Long-term management of elderly patients with rheumatoid arthritis treated with tocilizumab: comparison of patients over and under 75 years old","volume":"12","author":"Fautrel","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ero.2025.11.018_bib0021","unstructured":"Roche, Fachinformation RoActemra\u00ae i.v., March 2024."},{"key":"10.1016\/j.ero.2025.11.018_bib0022","unstructured":"Roche, RoActemra\u00ae Fertigpen, March 2024."},{"key":"10.1016\/j.ero.2025.11.018_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75673-7","article-title":"Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs","volume":"10","author":"Abuhelwa","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ero.2025.11.018_bib0024","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/kez535","article-title":"Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis","volume":"59","author":"Sch\u00e4fer","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ero.2025.11.018_bib0025","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10067-016-3183-3","article-title":"Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study","volume":"35","author":"Gardette","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ero.2025.11.018_bib0026","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3899\/jrheum.140673","article-title":"Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient","volume":"42","author":"Pers","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ero.2025.11.018_bib0027","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3899\/jrheum.190282","article-title":"Effectiveness of tocilizumab in patients with rheumatoid arthritis is unaffected by comorbidity burden or obesity: data from a US registry","volume":"47","author":"Pappas","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ero.2025.11.018_bib0028","unstructured":"Behrens F, Aringer M, Strotkamp D, Wassenberg S, Burmester G-R, Amberger C. Subcutaneous tocilizumab is effective and safe in different body mass index (BMI) categories (non-interventional study ARATA). Poster RA.34 presented at: Deutscher Rheumatologiekongress; 2023 Aug 30 to Sep 2; Leipzig, Germany. [cited 2025 Jan 22]. Available from: https:\/\/www.egms.de\/en\/meetings\/dgrh2023\/23dgrh180.shtml"},{"key":"10.1016\/j.ero.2025.11.018_bib0029","first-page":"676","article-title":"SAT0234 Influence of body mass index on outcomes in patients with rheumatoid arthritis treated with tocilizumab [abstract]","volume":"73","author":"Vollmer","year":"2014"},{"key":"10.1016\/j.ero.2025.11.018_bib0030","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1136\/ard.2010.132845","article-title":"Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab","volume":"70","author":"Ogata","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.018_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196368","article-title":"Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study","volume":"13","author":"Otsuka","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ero.2025.11.018_bib0032","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/OARRR.S302679","article-title":"Improvement of HbA1c in patients with type 2 diabetes mellitus and rheumatoid arthritis treated with bDMARDs","volume":"13","author":"Lurati","year":"2021","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.ero.2025.11.018_bib0033","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.kint.2017.11.025","article-title":"Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease","volume":"93","author":"Sumida","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ero.2025.11.018_bib0034","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jjcc.2017.08.008","article-title":"Chronic kidney disease, inflammation, and cardiovascular disease risk in rheumatoid arthritis","volume":"71","author":"Kochi","year":"2018","journal-title":"J Cardiol"},{"key":"10.1016\/j.ero.2025.11.018_bib0035","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/rheumatology\/ket169","article-title":"The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis","volume":"52","author":"Matcham","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ero.2025.11.018_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217412","article-title":"New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - implications from the prospective multicenter VADERA II study","volume":"14","author":"Englbrecht","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ero.2025.11.018_bib0037","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2215-0366(18)30255-4","article-title":"Rheumatoid arthritis and depression: an inflammatory perspective","volume":"6","author":"Nerurkar","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ero.2025.11.018_bib0038","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/rheumatology\/kex391","article-title":"Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis","volume":"57","author":"Choy","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ero.2025.11.018_bib0039","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.018_bib0040","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ero.2025.11.018_bib0041","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","article-title":"Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.018_bib0042","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fmed.2019.00118","article-title":"Infections in the elderly critically-Ill patients","volume":"6","author":"Esme","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ero.2025.11.018_bib0043","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s00125-024-06102-x","article-title":"Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment","volume":"67","author":"Holt","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.ero.2025.11.018_bib0044","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ackd.2019.01.004","article-title":"Immune dysfunction and risk of infection in chronic kidney disease","volume":"26","author":"Syed-Ahmed","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ero.2025.11.018_bib0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14740\/gr784w","article-title":"Symptomatic diverticular disease in patients with severely reduced kidney function: higher rates of complications and transfusion requirement","volume":"10","author":"Dirweesh","year":"2017","journal-title":"Gastroenterology Res"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305070812500117X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305070812500117X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:53:58Z","timestamp":1787716438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S305070812500117X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S305070812500117X"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.018","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab in German patients with RA: real-world evidence from the noninterventional studies ARATA and ICHIBAN","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}